To boost availability of molecular profiling solutions for personalised cancer treatment...
Advancing personalised medicine has become a key goal for many pharma firms, evident from the rising number of such therapies under clinical development. In 2022 alone, 12 new personalised medicines were approved, marking these treatments as accounting for at least a quarter of new drug approvals over the past eight years. This contrasts sharply with a decade ago when personalised medicines constituted less than 10 per cent of new approvals annually, according to The Personalised Medicine Coalit...
Early diagnosis is crucial to preventing complications, limiting the spread of the disease...
Expanding market access of anatomic pathology workflow technologies across Europe ...
Providing new value in cancer diagnosis with synergy of biomarker discovery and digital technology...
Leading a dynamic panel in Bali, Siemens Healthineers underscores the power of digital innovation and public-private partnerships in transforming Indonesia’s healthcare landscape, driving accessibility, and enhancing clinical outcomes across the nation...
Company announces $100 Million in total funding from new and existing investors to advance medical innovation...
Overcoming the limitations of current methods that rely on biofluid samples...
PoC breath diagnostics detecting volatile organic compound biomarkers...
First and only rapid syphilis test with in-home results in minutes, addressing growing epidemic ...
![[L-R]: Ms. Vivien Tan, XP Business Manager, Siemens Healthineers ASEAN; Prof. Dr. dr. Lina Choridah, Sp.Rad (K), Chairwoman Indonesian Woman Imaging Society; Hendya Perbangkara, Head of Diagnostic Imaging, Siemens Healthineers Indonesia](/uploads/articles/l_r__ms_vivien_tan_xp_business_manager_siemens_healthineers_asean-24188.jpg)
